By Fineline Cube 
Eli Lilly and Company (NYSE: LLY) reported fourth‑quarter 2025 revenue of USD 19.29 billion, up 43% year‑on‑year (YOY), bringing full‑year revenue to USD 65.18 billion, a 45% YOY increase. The historic expansion was driven by its incretin portfolio, with volume growth of 46% partially offset by a 5% decrease in realized prices.
Financial Performance Summary
| Metric | Q4 2025 | Full‑Year 2025 | YOY Growth |
|---|---|---|---|
| Total Revenue | USD 19.29 B | USD 65.18 B | +45% |
| Volume Growth | — | +46% | — |
| Price Impact | — | -5% | — |
| 2026 Guidance | USD 80–83 B | — | +23–27% |
Key Product Sales Performance
| Product | Molecule | Indication | 2025 Sales (USD B) | YOY Growth |
|---|---|---|---|---|
| Mounjaro | Tirzepatide | Type 2 diabetes | 22.97 | +99% |
| Zepbound | Tirzepatide | Obesity | 13.54 | +175% |
| Verzenio | Abemaciclib | Oncology (breast cancer) | 5.72 | +8% |
| Trulicity | Dulaglutide | Type 2 diabetes | 4.25 | -19% |
| Taltz | Ixekizumab | Immunology | 3.66 | +12% |
| Jardiance | Empagliflozin | Cardiovascular/metabolic | 2.14 | -36%* |
*Trulicity decline reflects patient switching to Mounjaro; Jardiance impacted by competitive dynamics.
2026 Outlook: Scale‑Up Year with Key Milestones
Pipeline Catalysts:
- Orforglipron (oral GLP‑1): Submitted for obesity in US/Japan and obesity+T2D in EU; regulatory decisions anticipated throughout 2026
- Retatrutide (triple G agonist): Following positive Phase III data in obesity+knee osteoarthritis, advancing as major focus for 2026 clinical updates
- Manufacturing Expansion: New USD 3 billion European facility dedicated to oral medicine capacity to meet demand
2026 Financial Guidance:
- Revenue: USD 80–83 billion
- Non‑GAAP EPS: USD 33.50–35.00
Strategic Implications
- Incretin Dominance: Mounjaro and Zepbound now represent 56% : of total revenue, cementing Lilly’s leadership in metabolic disease
- Oral GLP‑1 Disruption: Orforglipron approval would mark major shift from injectable to oral therapies, expanding addressable market
- Manufacturing Moat: $3 B European investment addresses supply constraints and supports next‑generation pipeline
- Market Valuation: 2026 guidance implies 23–27% revenue growth, reinforcing investor confidence despite competitive pressure
Forward‑Looking Statements
This brief contains forward‑looking statements regarding revenue projections, pipeline development, and commercial prospects for Eli Lilly. Actual results may differ due to competitive dynamics, regulatory approvals, and market conditions.-Fineline Info & Tech